Clincosm LogoSign in Get a demo

Hematological Disorders in Covid 19 Patients

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05182528
Collaborator
(none)
200
Enrollment
14.9
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

aim of the research is to detect hematological abnormalities in covid 19 patients and its correlation with the severity and outcome of the disease.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Covid 19 is an infectious disease caused by a newly discovered coronavirus.most people infected with the covid 19 virus will have mild to moderate respiratory illness and recover without specific treatment.older people and those with underlying medical problems like cardiac diseases,diabetes,any chronic respiratory disease and cancer are more likely to have serious illness.the covid 19 virus spreads primarily through droplets of saliva or discharge from the nose oral cavity when an infected person coughs or sneezes.people with covid19 have had a wide range of symptoms reported _ranging from mild to severe symptoms.symptoms may appear 2_14 days after exposure to the infection .any one can have mild to severe symptoms.people with these symptoms may have covid 19: fever or shivering,cough,shortness of breath,fatigue,body or muscle aches,headache,new loss of smell or taste ,sore thraot,congestion or running nose , nausea or vomiting,diarrhoea.

    The most common hematological clinical findings include lymphocytopenia,neutrophilia,eosinophilia,mild thrombocytopenia,and less frequently thrombocytosis,the presence of reactive lymphocytes has been reported only occasionally the leucocyte count may be normal,reduced or increased.according to a meta analysis leucocytosis,lymphopenia and thrombocytopenia are associated with greater severity and fatality in covid 19 cases

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Hematological Disorders in Covid 19 Patients
    Anticipated Study Start Date :
    Jan 1, 2022
    Anticipated Primary Completion Date :
    Jan 1, 2023
    Anticipated Study Completion Date :
    Apr 1, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Hematological disorders in covid 19 patients [Baseline]

      to detect hematological abnormalities in covid 19 patients and its correlation to outcome and severity of the disease

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    all covid 19 patients diagnosed by pcr or CT chest

    -

    Exclusion Criteria:
    • No

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Radwa mahmoud elsayed, Dr/Radwa mahmoud elsayed, Assiut University
    ClinicalTrials.gov Identifier:
    NCT05182528
    Other Study ID Numbers:
    • Hematological disorders
    First Posted:
    Jan 10, 2022
    Last Update Posted:
    Jan 10, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    COVID-19
    Hematologic Diseases

    Study Results

    No Results Posted as of Jan 10, 2022